Pages that link to "Q38025818"

The following pages link to Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib (Q38025818):

Displaying 19 items.

• Pharmacology and rationale for imatinib in the treatment of scleroderma (Q26825153) (← links)
• Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. (Q33840143) (← links)
• Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line (Q34703835) (← links)
• Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis (Q35545185) (← links)
• Epitope Specificity Determines Pathogenicity and Detectability of Anti-Platelet-Derived Growth Factor Receptor α Autoantibodies in Systemic Sclerosis. (Q35586763) (← links)
• Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis. (Q36901406) (← links)
• Animal models of scleroderma: current state and recent development (Q38154834) (← links)
• Systemic sclerosis and localized scleroderma--current concepts and novel targets for therapy (Q38636049) (← links)
• Strategy for treatment of fibrosis in systemic sclerosis: Present and future (Q38701990) (← links)
• Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). (Q38721897) (← links)
• Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment. (Q40292542) (← links)
• Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. (Q40785888) (← links)
• Ethnic difference may contribute to the efficacy of low-dose imatinib mesylate in systemic sclerosis (Q45842378) (← links)
• Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies (Q50243147) (← links)
• Use of biologics and other novel therapies for the treatment of systemic sclerosis. (Q51297193) (← links)
• Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report. (Q54120066) (← links)
• The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation. (Q54349169) (← links)
• Fulminant capillary leak syndrome in a patient with systemic sclerosis treated with imatinib mesylate. (Q55305517) (← links)
• IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis (Q90454739) (← links)